Research programme: antiviral nucleotides - Alios BioPharma

Drug Profile

Research programme: antiviral nucleotides - Alios BioPharma

Alternative Names: AL-516; Guanosine analogue - Alios BioPharma

Latest Information Update: 10 Nov 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alios BioPharma
  • Class Nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 07 Nov 2014 Alios BioPharma has been acquired by Johnson & Johnson
  • 06 Nov 2014 Antimicrobial data from a preclinical trial in Hepatitis C virus were released by Alios BioPharma
  • 15 Sep 2014 Preclinical trials in Hepatitis C in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top